Хронофармакология препаратов лития

Полный текст:   Только для подписчиков

Рекомендуемое оформление библиографической ссылки:

Арушанян Э.Б. Хронофармакология препаратов лития // Российский психиатрический журнал. 2017. №6. С. 54-59.

Аннотация

В научном обзоре представлены современные данные о фармакодинамике лития, используемого для лечения биполярного аффективного расстройства. Отмечено что, важную роль играет фактор времени. Хронотропные свойства лития могут влиять на функцию супрахиазматических ядер гипоталамуса, а также на процессы ингибирования киназы гликогенсинтазы-3 и мобилизацию эпифизарного гормона мелатонина.

Литература

1. Arushanian EB. [Complex relationships of the suprachiasmatic nuclei with the pineal gland and striatum as a unitary system which regulates the behavioural circadian rhythmicity]. Zhurnal vysshei nervnoi deiatelnosti im. I.P. Pavlova [Neuroscience and Behavioral Physiology]. 1996;46(1):16-22. Russian. 2. Arushanian EB. Glavnaia mishen - khronopsikhofarmakologiia (k 20-letiiu nauchnogo poiska sotrudnikov kafedry farmakologii). Meditcinskii vestnik Severnogo Kavkaza [Medical news of the North Caucasus]. 2007;6:3-16. Russian. 3. Arushanian EB. Unikalnyi melatonin. Stavropol, 2007. 360 p. Russian. 4. Arushanian EB. Melatonin – universalnyi stabilizator psikhicheskoi deiatelnosti. Zhurnal vysshei nervnoi deiatelnosti im. I.P. Pavlova [Neuroscience and Behavioral Physiology]. 2011;61(6):645-59. Russian. 5. Arushanian EB. Mesto tcentralnykh apparatov upravleniia biologicheskimi ritmami v geneze psikhopatologii i deistvii psikhotropnykh sredstv. Hronopatologia i hronomedizina. In: Khronopatologiia i khronomeditcina. Moscow; 2012. p. 122-40. Russian. 6. Arushanian EB. Ogranichenie okislitelnogo stressa kak osnovnaia prichina universalnykh zashchitnykh svoistv melatonina. Eksperimentalnaia i klinicheskaia farmakologiia [Russian Journal of Experimental and Clinical Pharmacology]. 2012;75(5):44-9. Russian. 7. Arushanian EB, Ovanesov KB. [Role of pineal gland in pathogenesis of depression]. Zhurnal vysshei nervnoi deiatelnosti im. I.P. Pavlova [Neuroscience and Behavioral Physiology]. 1991;41:822-7. Russian. 8. Markova NA, Shvezova EF. [Stress-induced depression as a risk factor for Alzheimer`s disease: the role of glycogen synthase kinase-3]. Patogenez [Pathogenesis]. 2013;11(4):4-8. Russian. 9. Abe M, Herzog ED, Block GS. Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons. Neurorport. 2000;11:3261-4. 10. Abreu T, Braganca M. The bipolarity of light and dark: A review on bipolar disorder and circadian cycles. J. Affect. Disord. 2015;185:219-29. 11. Anderson G, Maes M. Oxidative/nitrosative stress and immuneinflammatory pathways in depression: treatment implications. Curr. Pharm. Res. 2014;20(23):3812-47. 12. Bellivier F, Geoffroy PA, Etan B. Sleep- and circadian rhythm-associated pathways as therapeutic targets in bipolar disorder. Expert. Opin. Ther. Targets. 2015;19(6):747-63. 13. Besing RC, Paul JR, Habitz M, et al. Circadian rhythmicity of active GSK3 isoforms modulates molecular clock gene rhythms in the suprachiasmatic nucleus. J. Biol. Rhythms. 2015;30(2):155-60. 14. Crofton EJ, Nenov MN, Zhang Y. Glycogen synthase kinase 3 beta alters anxiety-, depression-, and addiction-related behaviors and neuronal activity in the nucleus accumbens shell. Neuropharmacology. 2017;117:49-60. 15. Etan B, Dumaine A, Bellivier F. Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder. Hum. Mol. Genet. 2012;21(18):4030-7. doi: 10.1093/hmg/dds227. 16. Fomaro M, McCarthy MJ, De Berardis D, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatry Dis. Treat. 2013;9:243-51. 17. Geoffroy PA, Curis E, Courtin C, et al. Lithium response in bipolar disorders and core clock genes expression. World J. Biol. Psychiatry. 2017;16:1-31. doi: 10.1080/15622975.2017.1282174 18. Geoffroy PA, Etan B, Franchi JA, et al. Melatonin and melatonin agonist as adjunctive treatment in bipolar disorders. Curr. Pharm. Des. 2015;21:3352-8. 19. Geoffroy PA, Samalin L, Lorca P, et al. Influence of lithium jn sleep and chronotypes in remitted patients with bipolar disorders J. Affect. Disord. 2016;204;32-39. 20. Gonzalez R. The relationship between bipolar disorder and biological rhythms. J. Clin. Psychiatry. 2014;75(4):323-31. 21. Iwahana E, Akiyama M, Miyakawa K, et al. Effect of lithium on the circadian rhythms of locomotor activity and glycogen synthase kinase-3 expression in the mouse suprachiasmatic nuclei. Eur. J. Neurosci. 2004;19(8):2281-7. 22. Jope RS, Roh MS. Glycogen synthase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Curr. Drug Targets. 2006;7(11):1421-34. 23. Kaladchibachi SA, Doble B, Anthonopoulos N, et al. Glycogen synthase kinase 3, circadian rhythms, and bipolar disorder: a molecular link in the therapeutic action of lithium. J. Circadian. Rhythms. 2007;5:3-10. 24. Kinoshita C, Miyazaki K, Ishida N. Chronic stress affects PERIOD 2 expression through glycogen synthase kinase-3 phosphorylation in the central clock. Neuroreport. 2012;23(2):98-102. doi: 10.1097/WNR.0b013e32834e7ec2 25. Luca A, Calandia C, Luca M. GSK3 signalling and redox status in bipolar disorder: evidence from lithium efficacy. Oxid. Med. Cell Longev. 2016;30:547-550. doi: 10.1155/2016/3030547. 26. McClung CA. Role of the clock gene in bipolar disorder Cold. Spring Harb. Symp. Quant. Biol. 2007;72:637-44. doi: 10.1101/sqb.2007.72.031. 27. Milhiet V, Boudebesse C, Bellivier F, et al. Circadian abnormalities as markers of susceptibility in bipolar disorders. Front. Biosci. 2014;6:120-37. 28. Moreira J, Geoffroy PA. Lithium and bipolar disorder: Impacts from molecular to behavioural circadian rhythms. Chronobiol. Int. 2016;33(33):351-73. doi: 10.3109/07420528.2016.1151026. 29. Murray G, Harvey A. Circadian rhythms and sleep in bipolar disorder. Bipol. Disord. 2010;12(5):459-72. doi: 10.1111/j.1399-5618.2010.00843.x. 30. Nierenberg AA. Low-dose buspirone, melatonin and low-dose bupropion added to mood stabilizers for severe treatment-resistant bipolar depression. Psychother. Psychosom. 2009;78(6):391-3. doi: 10.1159/000235985. 31. Reiter RJ, Calvo JR, Karbownik KH. Melatonin and its relation to the immune system and inflammation. Ann. N.Y. Acad. Sci. 2000;917:376-86. 32. Seggie J, Westiuk ES, Grota L. Lithium and circadian patterns of metabolism in the retina, hypothalamus, pineal and serum. Prog. Neuropharmacol. Biol. Psychiatry. 1987;11(2-3):325-34. 33. Souza LG, Wilhelm EA, Bortrolatto CF, et al. The protective effect of melatonin against brain oxidative stress and hyperlocomotion in a rat model of mania induced by ouabain. Behav Brain Res. 2014 Sep 1;271:316-24. doi: 10.1016/j.bbr.2014.06.030. Epub 2014 Jun 21. 34. Valvassori SS, Dal-Pint GC, Resende WR, et al. Lithium and valproate act on the GSK-3β signaling pathway to reverse manic-like behavior in an animal model of mania induced by ouabain. Neuropharmacology. 2017 May 1;117:447-59. doi: 10.1016/j.neuropharm.2016.10.015. Epub 2016 Oct 24. 35. Valvassori SS, Rezin GT, Ferreira CL, et al. Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with d-amphetamine. J. Psychiatry Res. 2010;44(14):903-9.

Метрики статей

Загрузка метрик ...

Metrics powered by PLOS ALM